Pharmalink's current portfolio includes two clinical phase products targeting niche indications with compelling clinical data and which represent clearly defined commercial opportunities. Each product candidate draws on the proven expertise of the Pharmalink development team and some of the leading science from Swedish medical research institutions.
| Project | Therapy | Phase I | Phase II | Phase III | Pre-license sales |
|
|
Nefecon (PL-56) |
IgA Nephritis | |||||
|
Busulipo (MZH-2) |
Conditioning prior to transplantation | |||||
|
Xepol (XP-28) Sold to Grifols |
Postpolio syndrome | |||||